Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency
Phase 3
Completed
- Conditions
- Factor VII Deficiency
- Interventions
- Biological: Eptacog alfa, biosimilarBiological: Novoseven
- First Posted Date
- 2017-03-14
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- AryoGen Pharmed Co.
- Target Recruit Count
- 24
- Registration Number
- NCT03079063
- Locations
- 🇮🇷
Hemophilia Center - Hematology & Oncology Dept. Shiraz University of Medical Science, Shiraz, Iran, Islamic Republic of
🇮🇷Comprehensive Hemophilia Care Center, Tehran, Iran, Islamic Republic of
© Copyright 2025. All Rights Reserved by MedPath